Associated Papers
Structural insights into non-hotspot KRAS mutations and their potential as targets for effective cancer therapies.
Ding C et al.
Journal of Biomolecular Structure & Dynamics, 2025
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer.
Vlachavas EI et al.
Molecular Oncology, 2025
39876058 (PubMed )
Supplement: MOL2-19-1751-s009.xlsx › Sheet_1
Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation.
Czyzyk D et al.
Nature Communications, 2025
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
39484452 (PubMed )
Supplement: media-2.zip › Extended_Data_Tables › Extended_Data_Table_1.xlsx › KRAS_GOF_DMS_Screen
Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target.
Vande Voorde J et al.
Nature Metabolism, 2023
37580540 (PubMed )
Supplement: 42255_2023_857_MOESM10_ESM.xlsx › Extended_data_5A
An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
Yang M et al.
Bmc Cancer, 2022
35272617 (PubMed )
Supplement: 12885_2022_9344_MOESM5_ESM.xlsx › 677_CRCs
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific.
Cook JH et al.
Nature Communications, 2021
33753749 (PubMed )
Supplement: 41467_2021_22125_MOESM4_ESM.xlsx › SD4._mutational_signature_level
High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer.
Kim JE et al.
Experimental & Molecular Medicine, 2021
33753878 (PubMed )
Supplement: 12276_2021_583_MOESM1_ESM.zip › 210226_BJX6JPRP_EMM2020836R_Supplelemtary_table_merged__1_.xls › Supplementary_Table_5
Phenotypic characterization of the novel, non-hotspot oncogenic KRAS mutants E31D and E63K.
Angeles AKJ et al.
Oncology Letters, 2019
Select a paper to view details